Receipt date: 08/27/2008 10697655 - GAU: 1611

Prosection (1003/000 - GAU, 101

Doc code: IDS PTO:SBC6s, (89-8)
Doc description: Information Disclosure Statement (IDS) Filed U.S. Faint and Trademark Office. U.S. Patert and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information under contains a valid Opin Control number.

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10697655		
	Filing Date		2003-10-31		
	First Named Inventor Micha		lichael Weller		
	Art Unit		1615		
	Examiner Name Klinke		linkel, Kortney L		
	Attorney Docket Numb	er	NGIO-001		

				U.S	.PATENTS	Remove		
Examiner Initial*			Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6127393		2000-10-03	FERNANDEZ			
	2	6407125		2002-06-18	FERNANDEZ			
	3	6407139		2002-06-18	ISAJI			
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	please click the Add button.	Add		
			U.S.P	ATENT APPL	ICATION PUBLICATIONS	Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020128290		2002-09-12	OHSHIMA ETSUO			
	2	20050239892		2005-10-27	MEYDANI			
	3	20060011113		2006 05 25	FUKUSHIMA			
			1		1	I		
					n information please click the Ade	d hutton Add		

			Filing Date 2003-10-31							
NFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor Micha			Micha	ael Weller				
		Art Unit				1615				
Not for submission under 37 CFR 1.99)			Exami	iner Naı	me	Klinke	el, Kortney L			
				Attorn	ey Docl	ket Numbe	er	NGIO-001		
Examiner nitial*	Cite No	Foreign Document Number ³	Country Code ² į		Kind Code ⁴	Publicatio Date	n ⊿	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	2 495 952	CA			2004-03-04		KISSEI PHARMACEUTICAL		
	2	1369114	EP			2002-06-0	, т	ERNESS		
	3	2003-026575	JP			2003-01-29) F	ROHTO PHARMA		
	4	2005-089345	JP			2003-09-10	5 Т	ENDOU		
	5	2006/053390	wo			2006-05-26		NGIOGEN PHARMACEUTICALS		
f you wis	h to a	ld additional Foreign Pa	tent Doc	ument	citation	informatio	n plea	ase click the Add buttor	Add	
			NON-	PATEN	IT LITE	RATURE	DOC	UMENTS	Remove	
Examiner nitials*										T5
	1	AZUMA, H. et al. (1976) "Pharmacological properties of N-(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5'), a new anti-atopic agent." Br. J. Pharmac 58: 483-488.								
	2	FALLARINO, F.; et al, "T cell apoptosis by tryptophan catabolism", Cell Death and Differentiation, 2002, 9 (10):1069-1077.								
	3	MOFFETT, JR et al. (200	(3) *Trypto	phan ar	nd the in	nmune resp	onse"	Immunology and Cell Bio	logy 81(4):247-265.	

Application Number

10697655

10697655 - GAU: 1611)

Receipt date: 08/27/2008

3		1000E0EE - 0.011-101-		
Receipt date: 08/27/2008	Application Number		10697655	10697655 - GAU: 161
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2003-10-31	
	First Named Inventor	Micha		
	Art Unit		1615	
	Examiner Name	Klinke	nkel, Kortney L	
	Attorney Docket Numb	er	NGIO-001	

	4	PLATTEN, M. et al (2005) "Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite." Science 310:850-855.						
	5	SHIGEKI, S et al. (1997) "Treatment of Keloid and Hypertrophic scares by iontophoretic transdermal delivery of ranilast." Scan J. Reconstr Hand Surg. 31(2):151-158.						
	6	TERNESS, P.; et al, "Inhibition of allogeneic T cell proliferation by indoleamine-2, 3-dioxygenase-expressing dentritic cells: Mediation of suppression by tryptophan metabolites", Journal of Experimental Medicine, 19 August 2002, 196 (4):447-457.						
	7	WIDNER, B., et al, "Tryptophan degradation to control T-cell responsiveness", Immunology Today, May 2000, 21 (5):250.						
	8	WIRLEITNER, B., et al., "Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects", Current Medicinal Chemistry, 2003, 10(16):1581-1591.						
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	Signa	ature /Kortney Klinkel/	Date Considered	12/03/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a								

1 See Kind Codes of USPTO Patent Documents at www.uSPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.